Acute Leukemias (2nd Ed., 2nd ed. 2021) Hematologic Malignancies Series
Coordonnateurs : Faderl Stefan H., Kantarjian Hagop M., Estey Elihu
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.
Stefan H. Faderl, MD, graduated in 1990 from Ludwig-Maximilians University in Munich, Germany. After fellowship training in Medical Oncology at the MD Anderson Cancer Center, Dr. Faderl joined the Leukemia Department at MD Anderson Cancer Center, where he worked on acute and chronic leukemias and rose to the rank of full professor. During this time he was engaged in the development of several new agents for the treatment of leukemia. In 2013, Dr. Faderl took the position as Chief of Leukemia at the John Theurer Cancer Center at Hackensack University Medical Center, where he successfully grew the clinical and clinical research programs. In 2017 he transitioned to the pharmaceutical industry where he continues developmental work towards new therapies for oncology patients. Dr. Faderl is the author of numerous journal articles, book chapters, abstracts, and editorials.
Hagop M. Kantarjian, MD, is a professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, TX. Also, he is the Samsung Distinguished Leukemia Chair in Cancer Medicine and a Special Fellow on Healthcare Policies at the Rice University Baker Institute in Houston, TX and and advocates for healthcare issues pertinent to patients with cancer and leukemia.Dr Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia. In the past 3 decades, he has made several contributions that improved the prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, eg, imatinib, dasatinib, nilotinib, bosutinib, ponatinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (H-CVAD regimen and its derivatives; antibodies including blinatumomab and inotuzumab), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations w
Provides detailed, state of the art information and guidance on the treatment of acute leukemias
Includes coverage of tumor biology and disease classification
New, fully updated edition with several additional chapters on important topics
Date de parution : 10-2021
Ouvrage de 289 p.
17.8x25.4 cm
Date de parution : 10-2020
Ouvrage de 289 p.
17.8x25.4 cm
Thèmes d’Acute Leukemias :
Mots-clés :
Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Relapsed and Refractory AML; Stem Cell Transplant; Investigational Therapies in AML; Burkitt's Acute Lymphoblastic Leukemia; Central Nervous System Involvement; Emergencies in ALL; Investigational Therapies in ALL; Philadelphia Chromosome